|
End-of-day quote
Egyptian Exchange
20/08/2026
|
5-day change | 1st Jan Change | ||
| 425.03 EGP | -10.14% |
|
-18.42% | +567.76% |
| 08-13 | GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
Chart: Technical Analysis
Stock exchange
Egyptian Exchange
BIOC 425.03 £
-10.14%
80.46M
£
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Egyptian Exchange
| BIOC | 425.03EGP | -10.14% | 80.46M £ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 550 | 550 | 521.01 |
| Spread/Res. | -22.72% | -22.72% | -18.42% |
| Spread/Supp. | +136.67% | +136.67% | +144.44% |
| Support | 179.59 | 179.59 | 173.88 |
- Stock Market
- Stocks
- BIOC Stock
- Charts GlaxoSmithKline S.A.E
Select your edition
All financial news and data tailored to specific country editions
